Aerie Pharmaceuticals, Inc. Appoints Richard J. Rubino as Chief Financial Officer

Aerie Pharmaceuticals, Inc. Appoints Richard J. Rubino as Chief Financial Officer

10/18/2012 9:38:09 AM

BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C.--Aerie Pharmaceuticals, a biotechnology company focused on the discovery and development of novel treatments for glaucoma, today announced the appointment of Richard J. Rubino to the position of Chief Financial Officer. Mr. Rubino has over 30 years of financial, business and strategic planning experience, most recently with Medco Health Solutions, Inc. Thomas van Haarlem, M.D., President and Chief Executive Officer of Aerie Pharmaceuticals, commented, "Mr. Rubino joins Aerie at a very exciting time for the Company as we advance through Phase 2 clinical studies for two of our first-in-class products. His extensive financial leadership and strategic planning experience in the healthcare industry brings an important skill set to the management team. Also, Mr. Rubino's strong networks in the financial and payor communities will play an important role in the growth and development of Aerie. We are pleased to have someone of Rich's caliber join our Executive Team."

Suggested Articles

Myovant’s uterine fibroid drug reduced blood loss in nearly three-quarters of patients, trouncing placebo in the second of two phase 3 studies.

The cystic fibrosis biotech unveiled Belous’ appointment alongside news of the promotion of Geoff Gilmartin to the CMO position.

The series C round is the latest in a series of boosts for Frequency’s attempts to tackle hearing loss through the activation of progenitor cells.